Pharming Group N.V. (PHAR) AI Stock Analysis

Pharming Group N.V. is a biopharmaceutical company based in Leiden, the Netherlands, dedicated to advancing protein replacement therapies and precision medicines for rare diseases and unmet medical needs. The company's flagship product, Ruconest, is a recombinant human C1 esterase inhibitor developed for the treatment of acute hereditary angioedema. Its development pipeline includes rhC1INH for conditions such as pre-eclampsia, acute kidney injury, and COVID-19, leniolisib for patients with activated PI3K delta syndrome, and alpha-glucosidase therapy for Pompe and Fabry diseases. Pharming Group N.V. also maintains strategic collaborations with Novartis and Orchard Therapeutics plc.

Pharming expanded revenue from $198.9M in FY2021 to $376.1M in FY2025, recording a 5-year revenue CAGR of 12.1%. Annual revenue growth reached 26.6% in FY2025, lifting net income to $2.9M and operating margin to 5.6%, after net losses of -$10.5M in FY2023 and -$11.8M in FY2024. Gross margins have remained steady, standing at 87.9% in FY2025. Over the trailing twelve months, revenue totaled $366.5M with an operating margin of 1.5% and EPS of $0.13. In the latest quarter ended June 30, 2026, quarterly revenue fell 3.2% year-over-year and quarterly earnings declined 62.9%.

As of June 30, 2026, Pharming Group held $158.3M in cash and short-term investments against total debt of $113.3M, yielding a net cash position of $45.0M. The company maintains solid liquidity with a current ratio of 3.01 and a debt-to-equity ratio of 0.42 against shareholders' equity of $270.5M. In FY2025, operating cash flow reached $54.7M and free cash flow was $54.0M, with capital expenditures totaling $755,000. The share count change over 5 years was 0.0%.

Pharming trades at a trailing P/E of 72.0x and a forward P/E of 212.8x, both higher than the median of its US-listed Healthcare peers of 24.6x and 17.3x, respectively. Its enterprise value to EBITDA ratio of 19.0x also sits above the peer median of 12.0x, while its price-to-sales ratio of 1.8x is below the peer median of 4.1x. Over the past year, the stock fell 34.9%, compared to a 16.8% return for the S&P 500. Over five years, the stock dropped 0.8% against an 83.0% gain for the benchmark.

Wall Street analyst coverage includes 4 Strong Buy ratings and no Buy, Hold, Sell, or Strong Sell ratings. The mean price target is $34.35, representing a 267.0% upside compared to the last close of $9.36 on October 16, 2026. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $383.4M and EPS of $0.61. Pharming beat EPS estimates in 2 of the trailing 4 quarters, and its next earnings release is scheduled for November 5, 2026.

This page is an AI-written research summary of Pharming Group N.V. (PHAR). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: PHAR income statement, PHAR balance sheet, PHAR key metrics, PHAR analyst forecast, PHAR chart. See the PHAR stock overview for the latest quote and news.